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Abstract
Background: Inflammatory myofibroblastic tumour (IMT) is a benign, nonmetastasizing
proliferation of myofibroblasts with a potential for local infiltration, recurrence and persistent local
growth.
Case report: We report a case of a 51 year-old female, who had excision of a gallbladder tumour.
Histopathology showed it to be IMT of the gallbladder.
Conclusion: The approach to these tumours should be primarily surgical resection to obtain a
definitive diagnosis and relieve symptoms. IMT has a potential for local infiltration, recurrence and
persistent local growth.
Introduction
Inflammatory myofibroblastic tumour (IMT) is a rare
benign lesion that has been discussed in various organs
and tissues. They are well recognised in lung and upper
respiratory tract of children and young adults with a pre-
dilection for first and second decade. Intra-abdominal
forms of the disease are reported to occur most frequently
in the liver, followed by stomach, bowel, spleen, mesen-
tery [1] and extrahepatic bile duct [2]. The clinical presen-
tation will vary on the site involved. We report a case of
IMT of the gallbladder, which has not been previously
described. A case of inflammatory pseudotumour of the
gallbladder and bile ducts with synchronous lesion in the
lung, has been described, which subsided on high-dose
prednisolone therapy [3]. Another case of chronic chole-
cystitis with features of xanthogranulomatous inflamma-
tion due to the presence of a prominent inflammatory
infiltrate composed of plasma cells, lymphocytes, macro-
phages, foamy histiocytes and huge fibroblastic and
myofibroblastic proliferation was described by Corsi A et
al [4].
Case Report
A 51-year-old female presented with history of acute right
upper abdominal pain, localised abdominal signs and
raised inflammatory markers. Ultrasound scanning sug-
gested acute cholecystitis. The patient was explored ini-
tially by laparoscopy but converted to an open operation
at the referring hospital. An irresectable mass, which was
thought to be an advanced gallbladder carcinoma, was
found. Several needle biopsies were taken from the
tumour but the gallbladder was not excised. Histology of
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She developed obstructive jaundice postoperatively, ERCP
showed a distal bile duct stricture which was stented. CT
scan showed a mass lesion in the gallbladder area with
direct involvement of the liver and no metastatic disease
elsewhere (Figure 1). In view of the histological diagnosis
the patient underwent re-laparotomy through an
extended subcostal incision. Operative findings included
a tense, distended gallbladder containing stones, debris
and pus with a segment of transverse colon densely adher-
ent to the mass. An en-bloc cholecystectomy and limited
transverse colectomy with primary anastomosis was per-
formed. The mass was peeled off the first and second part
of duodenum, common bile duct and transverse mesoco-
lon. Intra-operative cholangiogram via the cystic duct
stump showed no biliary leakage and the dye flowed
freely into the duodenum with the biliary stent in situ.
On pathological examination, the tumour measured 12
cms. Microscopy of the resected mass showed the gall-
bladder wall to be replaced by proliferative spindle myofi-
broblastic cells arranged in fascicles, admixed with diffuse
chronic inflammatory cells including lymphocytes,
plasma cells and eosinophils with lymphoid aggregates.
In places hyalinised fibrous stroma was seen. No pleo-
morphism or vascular invasion was evident. Mitoses were
inconspicuous (Figure 2). The mass was seen to grow in
an infiltrating pattern with entrapment of adipocytes and
extending to the muscularis propria of colon from exter-
nally. The tumour extended to the resection margin. Four
CT scan showing the gallbladder inflammatory massFigure 1
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chemistry showed positivity for SMA (Figure 3) and cal-
ponin. ALK-1 was equivocal. However desmin,
caldesmon and CAM 5.2 were negative (Figure 4).
The postoperative period was uneventful. ERCP was done
at four weeks after operation with replacement of the stent
because of slight stricturing of the common hepatic duct.
No local recurrence was detected at six months follow-up
on CT scan.
Discussion
Inflammatory myofibroblastic tumour is a benign, non-
metastasizing proliferation of myofibroblasts with poten-
tial for recurrence and persistent local growth, similar in
some respect to the fibromatoses [5]. IMT is associated
with constitutional symptoms and it has been variously
termed plasma cell granuloma, inflammatory pseudotu-
mour, inflammatory myofibrohistiocytic proliferation to
reflect divergent views concerning its pathogenesis and
level of malignancy. The attributes of a myofibroblast
places it midway between a fibroblast and a smooth mus-
cle cell and it appears capable of functional and pheno-
typic modulation.
Myofibroblastic tumours fall into four main groups: the
family of reactive fascitis like lesions, a group of benign
lesions (e.g. Mammary myofibroblastoma, intranodal
Photomicrograph showing features of inflammatory myofibroblastic tumour (Haematoxylin and Eosin × 50)Figure 2
Photomicrograph showing features of inflammatory myofibroblastic tumour (Haematoxylin and Eosin × 50)Page 3 of 6
(page number not for citation purposes)
World Journal of Surgical Oncology 2005, 3:24 http://www.wjso.com/content/3/1/24myofibroblastoma, angiomyofibroblastoma and dermat-
omyofibroma), the locally aggressive fibromatoses (either
superficial or deep) which share features of fibroblasts
and myofibroblasts in varying degree and finally sarcomas
showing myofibroblastic differentiation (low grade
lesions – infantile myofibroblastic sarcoma, inflamma-
tory myofibroblastic tumours, low grade myofibroblastic
sarcoma, inflammatory fibrosarcoma [6] and high grade
lesions – malignant fibrous histiocytoma) [7]. An aber-
rant or exaggerated response to tissue injury without an
established cause has generally been favoured as the
pathogenesis of the inflammatory pseudotumour or IMT.
An immunological pathogenesis remains a possibility.
Tumours with myofibroblast as the principal cell type are
designated as IMT. The IMT and inflammatory fibrosar-
coma appear to have many overlapping clinical and path-
ological features. These tumours are histogenetically
related and if they are separate entities, they are differenti-
ated more by degrees than absolutes [8]. IMT of the gas-
trointestinal tract is extremely rare and differ clinically,
histologically and immunohistochemically from inflam-
matory fibroid polyps though both have a prominent
inflammatory infiltrate admixed with spindle-shaped
fibroblasts/ myofibroblasts set in a collagenous, fibrovas-
cular or myxoid stroma [9].
The inflammatory myofibroblastic tumours are well cir-
cumscribed but rarely encapsulated. They usually have a
Photomicrograph showing immunohistocemical positive staining with smooth muscle actin (×100)Figure 3
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necrosis or calcification may be found. Multicentric
lesions are rare. IMT is composed of fascicles of bland
myofibroblastic cells admixed with a prominent inflam-
matory infiltrate consisting of lymphocytes, plasma cells,
macrophages and eosinophils. The lack of atypia, hyper-
chromasia and abnormal mitotic figures are pointers
towards a benign lesion. The spindle cells stain positively
for smooth muscle actin and vimentin but are negative for
S100, desmin, CD100, cytokeratin, CD35 and latent
membrane protein. Differential diagnosis includes calci-
fying fibrous pseudotumour [10,11] inflammatory fibro-
sarcoma, follicular dendritic cell tumour and
gastrointestinal autonomic nerve tumours. Calcifying
fibrous pseudotumour is a benign fibrous lesion charac-
terised by three distinctive features: a collection of dense,
hyalinized collagen interspersed with benign-appearing
spindle cells, psammomatous or dystrophic calcification,
and a lymphoplasmocytic inflammatory infiltrate of vari-
able intensity [11]. Inflammatory fibrosarcoma is histoge-
netically related but is regarded as malignant on the basis
of the high rate of local recurrence, multiple peritoneal
implants, locally aggressive behaviour, distant metastases
and tumour related deaths. IMT and inflammatory fibro-
sarcoma may be two ends of a part of a neoplastic contin-
uum of myofibroblastic proliferation with increasing
cellular atypia and aggressiveness [8]. ALK immunostain-
ing is detected in 36% to 60% of cases in a fibrillary or
Photomicrograph showing immunohistocemical negative staining with desmin (× 100)Figure 4
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granular distribution in cytoplasm or nucleus, with occa-
sional cell and nuclear membranous accentuation [12].
The presence of chromosomal aberrations indicates that
IMT is a neoplastic proliferation [13]. IMT are clonal and
a proportion (30 – 40%) has reproducible cytogenetic
abnormalities involving the region of the anaplastic
lymphoma kinase (ALK1) gene on chromosome 2 [10].
Inflammatory myofibroblastic tumours show a wide spec-
trum of cellular atypia and biological behaviour with p53
and MDM2 expression. However the alterations in the
p53 pathway seem not to play a major role in the patho-
genesis of inflammatory myofibroblastic tumour [14].
There is no regular vascular pattern thus there is variable
contrast enhancement on CT scans. On magnetic reso-
nance imaging, hepatic IMT appears as a mass or as an
area of periportal soft tissue infiltration. The mass is
hypointense on T1-W and slightly hyperintense relative to
surrounding liver parenchyma on T2-W image [15]. The
prognosis of this tumour is generally considered to be
favourable with no reports of malignancy [16]. Twenty-
two cases have been reported in the pancreatic region
[17]. Coffin CM et al [5] have reported 84 cases with a
median age of 9 years (3 months to 46 years) occurring at
various sites (abdomen, retroperitoneum or pelvis (61
cases); head and neck including upper respiratory tract
(12 cases); trunk (8 cases); and extremities (3 cases)) and
ranging in size from 1 to 17 cms. Excision was performed
in 69 cases and clinical follow-up in 53 cases revealed 13
patients (25%) had one or more recurrences at intervals of
1–24 months. Histological confirmation is always
required before diagnosis and treatment, to differentiate it
from malignant tumour. Misdiagnosis has led some
patients to be inappropriately treated with chemotherapy
[12]. The therapeutic approach to these tumours should
rely primarily on surgical resection in order to obtain a
definitive diagnosis as well as to relieve symptoms. IMT
has a potential for local infiltration, recurrence and per-
sistent local growth. Local recurrence may occur many
years later and thus strict follow-up after surgery is
required.
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